A study has found that short dual antiplatelet therapy (dapt) may be sufficient for patients with contemporary drug-eluting stents (des). The study's findings were reported alongside other coronary news, including the use of drug-coated balloons and beta-blockers in stemi. Data from another study suggests that one type of des, the orsiro des, may outperform other ultrathin strut drug-eluting stents.